News
CMOPF
55.00
NaN%
--
Weekly Report: what happened at CMOPF last week (0414-0418)?
Weekly Report · 4d ago
Weekly Report: what happened at CMOPF last week (0407-0411)?
Weekly Report · 04/14 10:24
Weekly Report: what happened at CMOPF last week (0331-0404)?
Weekly Report · 04/07 10:23
Cosmo Appoints Federico Sommariva as Chief Legal Counsel
Newsfile · 04/01 05:02
Weekly Report: what happened at CMOPF last week (0324-0328)?
Weekly Report · 03/31 10:30
Weekly Report: what happened at CMOPF last week (0317-0321)?
Weekly Report · 03/24 10:23
Cosmo Pharmaceuticals reports FY results
Seeking Alpha · 03/21 15:55
Cosmo Pharmaceuticals publishes Annual Report 2024
Newsfile · 03/21 06:13
Weekly Report: what happened at CMOPF last week (0310-0314)?
Weekly Report · 03/17 10:29
Weekly Report: what happened at CMOPF last week (0303-0307)?
Weekly Report · 03/10 10:31
Cosmo Pharmaceuticals N.V. reports FY results
Seeking Alpha · 03/06 21:53
Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025
Newsfile · 03/06 06:01
Weekly Report: what happened at CMOPF last week (0224-0228)?
Weekly Report · 03/03 10:30
Weekly Report: what happened at CMOPF last week (0217-0221)?
Weekly Report · 02/24 10:30
Weekly Report: what happened at CMOPF last week (0210-0214)?
Weekly Report · 02/17 10:28
Cosmo to Host Investor Day on April 9, 2025
Newsfile · 02/12 06:01
Cosmo names Andrea Cherubini as chief AI officer
Seeking Alpha · 02/11 08:22
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
Newsfile · 02/11 06:02
Weekly Report: what happened at CMOPF last week (0203-0207)?
Weekly Report · 02/10 10:25
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne
Newsfile · 02/10 06:02
More
Webull provides a variety of real-time CMOPF stock news. You can receive the latest news about Cosmo Pharmaceuticals Nv through multiple platforms. This information may help you make smarter investment decisions.
About CMOPF
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.